These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 5556528)

  • 1. Vehicle design for a new topical steroid, fluocinonide.
    Ostrenga J; Haleblian J; Poulsen B; Ferrell B; Mueller N; Shastri S
    J Invest Dermatol; 1971 May; 56(5):392-9. PubMed ID: 5556528
    [No Abstract]   [Full Text] [Related]  

  • 2. Design of the optimal topical system for fluocinonide.
    Reinstein J; Ostrenga J; Haleblian J; Shastri S; Poulsen B; Katz M
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):Suppl 67:13-8. PubMed ID: 5291642
    [No Abstract]   [Full Text] [Related]  

  • 3. Status of topical therapy.
    Stoughton RB
    Clin Pharmacol Ther; 1974 Nov; 16(5 Part 2):869-72. PubMed ID: 4425251
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.
    Schwarb FP; Imanidis G; Smith EW; Haigh JM; Surber C
    Pharm Res; 1999 Jun; 16(6):909-15. PubMed ID: 10397613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of topical steroids.
    Barry BW
    Dermatologica; 1976; 152 Suppl 1():47-65. PubMed ID: 955238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Various vagaries of vasoconstriction.
    Burdick KH
    Arch Dermatol; 1974 Aug; 110(2):238-42. PubMed ID: 4855376
    [No Abstract]   [Full Text] [Related]  

  • 7. [Reflexphotometric determinations of vasoconstriction after topical application of steroids. Method, reliability, errors (author's transl)].
    Zaun H; Altmeyer P
    Arch Dermatol Forsch; 1973; 247(4):379-86. PubMed ID: 4767633
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and evaluation of ointment and cream vehicles for a new topical steroid, fluclorolone acetonide.
    Malone T; Haleblian JK; Poulsen BJ; Burdick KH
    Br J Dermatol; 1974 Feb; 90(2):187-95. PubMed ID: 4819137
    [No Abstract]   [Full Text] [Related]  

  • 9. Proceedings: Topical availability of hydrocortisone from different ointment bases.
    Ritschel WA; Kitzmiller KW; Serracino-Inglott A
    Rev Can Biol; 1973; 32():Suppl:91-7. PubMed ID: 4777607
    [No Abstract]   [Full Text] [Related]  

  • 10. The vasoconstrictor assay in bioequivalence testing: practical concerns and recent developments.
    Stoughton RB
    Int J Dermatol; 1992 Oct; 31 Suppl 1():26-8. PubMed ID: 1428464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in the formulation of vehicles for topical applications.
    Hadgraft JW
    Br J Dermatol; 1972 Oct; 87(4):386-9. PubMed ID: 4562170
    [No Abstract]   [Full Text] [Related]  

  • 12. Penetration and action of glucocorticoids.
    Schlagel CA
    Adv Biol Skin; 1972; 12():339-56. PubMed ID: 4579200
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of polyoxypropylene 15 stearyl ether and propylene glycol on percutaneous penetration rate of diflorasone diacetate.
    Turi JS; Danielson D; Woltersom JW
    J Pharm Sci; 1979 Mar; 68(3):275-80. PubMed ID: 423113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroid bioavailability assays. Correlation with a clinical study.
    Burdick KH
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):19-23. PubMed ID: 5291630
    [No Abstract]   [Full Text] [Related]  

  • 15. Topical corticosteroids.
    Maibach HI; Stoughton RB
    Med Clin North Am; 1973 Sep; 57(5):1253-64. PubMed ID: 4274734
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro penetration through the skin layers of topically applied glucocorticoids.
    Carrer V; Alonso C; Oliver MA; Coderch L
    Drug Test Anal; 2018 Oct; 10(10):1528-1535. PubMed ID: 29788546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical corticosteroid compounding.
    Oriba HA; Bucks DA
    J Am Acad Dermatol; 1990 Nov; 23(5 Pt 1):954. PubMed ID: 2254493
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors influencing the formulation of semisolid preparations with special reference to corticosteroid products.
    Worthington HE
    Acta Derm Venereol Suppl (Stockh); 1973; 53():29-34. PubMed ID: 4518660
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical steroid therapy in skin disease. A panel discussion.
    S Afr Med J; 1974 Aug; 48(42):suppl:1-8. PubMed ID: 4278512
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of a new corticosteroid, fluocinonide, in a scientifically designed base.
    Burdick KH
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):24-31. PubMed ID: 5291631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.